Literature DB >> 9788410

Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.

G M Videtic1, B J Fisher, F E Perera, G S Bauman, W I Kocha, M Taylor, M D Vincent, E A Plewes, C J Engel, L W Stitt.   

Abstract

BACKGROUND AND
PURPOSE: To determine the percentage of complete responders and the resectability rate for patients with locally advanced carcinoma of the rectum treated by 5-fluorouracil (5-FU) infusional chemotherapy and pelvic radiation.
MATERIALS AND METHODS: Between October 1992 and June 1996, 29 patients with a diagnosis of locally advanced unresectable rectal cancer received preoperative 5 FU by continuous intravenous infusion at a dose of 225 mg/m2/day concurrent with pelvic radiation (median 54 Gy/28 fractions). All patients were clinical stage T4 on the bases of organ invasion or tumor fixation. Median time for surgical resection was 6 weeks.
RESULTS: Median follow-up for the group was 28 months (range 5-57 months). Six patients were felt to be persistently unresectable or developed distant metastases and did not undergo surgical resection. Of the 29 patients, 23 proceeded to surgery, 18 were resectable for cure, 13 by abdominoperineal resection, 3 by anterior resection and 2 by local excision. Of the 29 patients, 4 (13%) had a complete response, and 90% were clinically downstaged. Of the 18 resected patients, 1 has died of his disease, 17 are alive, and 15 disease-free. The regimen was well tolerated; there was only one treatment-related complication, a wound dehiscence.
CONCLUSION: The combination of 5 FU infusion and pelvic radiation in the management of locally advanced rectal cancer is well tolerated and provides a baseline for comparison purposes with future combinations of newer systemic agents and radiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788410     DOI: 10.1016/s0360-3016(98)00214-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Preoperative chemoradiation for rectal cancer: kudos and a caution.

Authors:  Wayne S Kendal; Hartley S Stern
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

2.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

3.  Neoadjuvant radiochemotherapy for patients with locally advanced rectal cancer leads to impairment of the anal sphincter.

Authors:  Joerg Theisen; Werner K-H Kauer; Hjalmar Nekarda; Ludwig Schmid; Hubert J Stein; Joerg-Ruediger Siewert
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

Review 4.  Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

Authors:  Gunther Klautke; Rainer Fietkau
Journal:  Int J Colorectal Dis       Date:  2006-10-28       Impact factor: 2.571

Review 5.  Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer.

Authors:  Rolf Sauer
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 6.  Late small bowel toxicity after adjuvant treatment for rectal cancer.

Authors:  Matthias Guckenberger; Michael Flentje
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

7.  Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase II randomized study.

Authors:  Reena Engineer; K M Mohandas; P J Shukla; S V Shrikhande; U Mahantshetty; S Chopra; M Goel; S Mehta; P Patil; M Ramadwar; K Deodhar; S Arya; Shyam Kishore Shrivastava
Journal:  Int J Colorectal Dis       Date:  2013-01-29       Impact factor: 2.571

8.  Determining therapeutic approaches in the elderly with rectal cancer.

Authors:  Lara Maria Pasetto; Umberto Basso; Maria Luisa Friso; Salvatore Pucciarelli; Marco Agostini; Massimo Rugge; Giulietta Sinigaglia; Mario Lise; Guido Sotti; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.

Authors:  M W Saif; Shahrukh Hashmi; Daniel Zelterman; Khaldoun Almhanna; Richard Kim
Journal:  Int J Colorectal Dis       Date:  2007-10-02       Impact factor: 2.571

10.  Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial.

Authors:  Mostafa Abd Elwanis; Doaa W Maximous; Mohamed Ibrahim Elsayed; Nabiel N H Mikhail
Journal:  World J Surg Oncol       Date:  2009-06-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.